NOTE
13 – SEGMENT REPORTING
| A. | Information
about reported segment profit or loss and assets |
As
of June 30, 2026, the Company has two reportable segments: (i) Biotechnology activity, and (ii) Renewable energy projects. The Biotechnology
operating segment consists of MitoCareX from the acquisition date, and the Renewable energy projects operating segment consists of NITO
Renewable Energy, Inc. and Solar photovoltaic joint venture project.
The
CODM evaluates performance and allocates resources based primarily on segment operating loss. Prior period segment information has been
recast to conform to the current year presentation.
The
following table presents information about the Company’s reportable segments for the six and three months ended June 30, 2026 and
2025:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Six
months ended | | |
Three
months ended | |
| | |
June
30 | | |
June
30 | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Revenue from biotechnology activity | |
| - | | |
| - | | |
| - | | |
| - | |
| Cost related to biotechnology activity
(*) | |
| (434 | ) | |
| - | | |
| (310 | ) | |
| - | |
| Salaries and related expenses related to biotechnology
activity | |
| (582 | ) | |
| - | | |
| (325 | ) | |
| - | |
| Amortization of intangible
asset | |
| (202 | ) | |
| - | | |
| (102 | ) | |
| - | |
| Operating loss from Biotechnology
activity | |
| (1,218 | ) | |
| - | | |
| (737 | ) | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Revenue from renewable energy projects | |
| - | | |
| - | | |
| - | | |
| - | |
| Cost related to renewable
energy projects | |
| (19 | ) | |
| (130 | ) | |
| (15 | ) | |
| (59 | ) |
| Operating loss from renewable
energy projects | |
| (19 | ) | |
| (130 | ) | |
| (15 | ) | |
| (59 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Professional services | |
| (916 | ) | |
| (557 | ) | |
| (493 | ) | |
| (356 | ) |
| Share base compensation | |
| (1,399 | ) | |
| (2,029 | ) | |
| (250 | ) | |
| (1,988 | ) |
| Change in fair value of contingent consideration | |
| 203 | | |
| - | | |
| (139 | ) | |
| - | |
| Goodwill impairment | |
| (6,291 | ) | |
| - | | |
| - | | |
| - | |
| Depreciation | |
| (7 | ) | |
| - | | |
| (4 | ) | |
| - | |
| Other general and administrative
expenses | |
| (454 | ) | |
| (414 | ) | |
| (237 | ) | |
| (224 | ) |
| Total
Operating loss | |
| (10,101 | ) | |
| (3,130 | ) | |
| (1,875 | ) | |
| (2,627 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Interest of loans | |
| - | | |
| (77 | ) | |
| - | | |
| - | |
| Financing expenses, net | |
| (8,939 | ) | |
| (1,952 | ) | |
| (8,839 | ) | |
| (1,234 | ) |
| Other income | |
| 386 | | |
| - | | |
| - | | |
| - | |
| Changes in fair value
of investments measured under the fair value option | |
| 24 | | |
| (344 | ) | |
| (469 | ) | |
| (526 | ) |
| Income taxes | |
| 46 | | |
| - | | |
| 23 | | |
| - | |
| Net
loss | |
| (18,584 | ) | |
| (5,503 | ) | |
| (11,160 | ) | |
| (4,387 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| (*) | Costs
related to biotechnology activity primarily consist of subcontractors engaged in research and development activities |
|